RRx-001, a Small Molecule Anticancer Agent in Phase 3, Protects Against Inflammasome-Driven Diseases

Time: 11:30 am
day: Day 1 - Track B - Morning

Details:

  • Evaluate strategy and execution of drug design and translational development
  • Understanding relevant pathology of disease and most up to date learnings on the inflammasome mechanisms, drug design, and patient population
  • Exploring the latest data, potential biomarkers, challenges, and future directions

Speakers: